

Bacterial Vaginosis (Infectious Disease) - Drugs in Development, 2021

<https://marketpublishers.com/r/B15CCF66ABF9EN.html>

Date: March 2021

Pages: 82

Price: US\$ 2,000.00 (Single User License)

ID: B15CCF66ABF9EN

Abstracts

Bacterial Vaginosis (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Drugs in Development, 2021, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 3, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Bacterial Vaginosis - Overview
- Bacterial Vaginosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bacterial Vaginosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bacterial Vaginosis - Companies Involved in Therapeutics Development
- Dare Bioscience Inc
- Evoform Biosciences Inc
- Ferring Pharmaceuticals Inc
- Guangdong Longchuangji Pharmaceutical Co Ltd
- Hammock Pharmaceuticals Inc
- Hennepin Life Sciences LLC
- Melinta Therapeutics Inc
- MyBiotics Pharma Ltd
- Next Science Ltd
- Osel Inc
- PhagoMed Biopharma GmbH
- Pharmiva AB
- Profem GmbH
- Starpharma Holdings Ltd
- TenNor Therapeutics Ltd
- Toltec Pharmaceuticals LLC
- Bacterial Vaginosis - Drug Profiles
- (citric acid + lactic acid + potassium bitartrate) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- astodimer - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
Biologic for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clindamycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LACTIN-V - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBXSD-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metronidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PM-477 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Prof-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

radezolid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

subtilosin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNP-2198 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacterial Vaginosis - Dormant Projects

Bacterial Vaginosis - Discontinued Products

Bacterial Vaginosis - Product Development Milestones

Featured News & Press Releases

Dec 07, 2020: Dar? Bioscience announces positive topline results from DARE-BVFREE, a phase 3 trial of DARE-BV1 in patients diagnosed with bacterial vaginosis

Sep 25, 2020: VivaGel BV secures TGA approval for prevention of BV

Aug 20, 2020: Dar? Bioscience announces publication of DARE-BV1 proof of concept study for the treatment of bacterial vaginosis

Jun 17, 2020: Dar? Bioscience announces initiation of pivotal Phase 3 study of DARE-BV1 in patients with bacterial vaginosis

Jun 16, 2020: VivaGel BV launched in central and eastern European countries

May 13, 2020: Osel's live biotherapeutic product demonstrates efficacy in phase 2b study of bacterial vaginosis

Apr 28, 2020: Dare Bioscience CEO to participate in Maxim Group's Infectious Disease

Virtual Conference

Mar 10, 2020: Dare Bioscience receives FDA fast track designation for DARE-BV1 for the treatment of bacterial vaginosis

Dec 18, 2019: Dar? Bioscience announces FDA clearance of IND application for DARE-BV1 for Bacterial Vaginosis to commence pivotal phase 3 clinical study

Nov 13, 2019: Starpharma announces UK launch of VivaGel BV

Sep 28, 2019: Congratulations to Guangdong Longchuangji Pharmaceutical a subsidiary of Qiangji Pharmaceutical, for obtaining clinical approval for the "Vaginal Lactobacillus Double Live Capsules" developed

Sep 03, 2019: VivaGel BV regulatory approvals continue in Asia

Aug 15, 2019: First Asian regulatory approvals received for VivaGel BV

Aug 12, 2019: Dar? Bioscience receives QIDP Designation from the FDA for DARE-BV1 for the treatment of Bacterial Vaginosis

Aug 08, 2019: Dare announces presentation of positive clinical findings for vaginal administration of novel formulation of clindamycin phosphate for the treatment of bacterial vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Bacterial Vaginosis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Bacterial Vaginosis - Pipeline by Dare Bioscience Inc, 2021
Bacterial Vaginosis - Pipeline by Evofem Biosciences Inc, 2021
Bacterial Vaginosis - Pipeline by Ferring Pharmaceuticals Inc, 2021
Bacterial Vaginosis - Pipeline by Guangdong Longchuangji Pharmaceutical Co Ltd, 2021
Bacterial Vaginosis - Pipeline by Hammock Pharmaceuticals Inc, 2021
Bacterial Vaginosis - Pipeline by Hennepin Life Sciences LLC, 2021
Bacterial Vaginosis - Pipeline by Melinta Therapeutics Inc, 2021
Bacterial Vaginosis - Pipeline by MyBiotics Pharma Ltd, 2021
Bacterial Vaginosis - Pipeline by Next Science Ltd, 2021
Bacterial Vaginosis - Pipeline by Osel Inc, 2021
Bacterial Vaginosis - Pipeline by PhagoMed Biopharma GmbH, 2021
Bacterial Vaginosis - Pipeline by Pharmiva AB, 2021
Bacterial Vaginosis - Pipeline by Profem GmbH, 2021
Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, 2021
Bacterial Vaginosis - Pipeline by TenNor Therapeutics Ltd, 2021
Bacterial Vaginosis - Pipeline by Toltec Pharmaceuticals LLC, 2021
Bacterial Vaginosis - Dormant Projects, 2021
Bacterial Vaginosis - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bacterial Vaginosis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Bacterial Vaginosis (Infectious Disease) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/B15CCF66ABF9EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B15CCF66ABF9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970